Myxoid liposarcoma: local relapse and metastatic pattern in 43 patients by Duerr, Hans Roland et al.
RESEARCH ARTICLE Open Access
Myxoid liposarcoma: local relapse and
metastatic pattern in 43 patients
Hans Roland Dürr1*, Jessica Rauh1, Andrea Baur-Melnyk2, Thomas Knösel3, Lars Lindner4, Falk Roeder5,6,
Volkmar Jansson1 and Alexander Klein1
Abstract
Background: Liposarcomas are the second most common type of soft tissue sarcomas, 30–50% of these are of
myxoid subtype. The aim of this retrospective study was to analyze the local control rate, the metastatic pattern
and survival of patients in a consecutive single-institution series.
Methods: From 1983 to 2015, 43 patients with myxoid liposarcoma of the extremities and trunk wall underwent
resections. The margin was defined as R0 (wide) or R1 (marginal). Patients were followed for evidence of local
recurrence or distant metastasis. Overall and recurrence-free survival was calculated.
Results: The mean age was 48.6 years. The lower extremity was involved in 40 cases, the mean tumour size was
12 cm. In 31 cases a wide and in 12 cases a marginal resection was performed. Grading was G1 in 14, G2 in 25
and G3 in 4 cases.
Nine patient died in follow-up, 4 of them with metastatic disease, all nonpulmonary. 5-year local recurrence (LR)
free survival was 82%. 4 (9.3%) patients developed LR (all R1). Overall survival (OS) was 81% after 5 and 72% after
10 years. In multivariate analysis age and Grading proved to be significant on OS. According to univariate analysis,
only age over 48 years and distant metastasis had a significant impact on overall survival.
Conclusions: Patients with myxoid liposarcomas have a good prognosis. Myxoid liposarcoma has a distinct pattern
of nonpulmonary metastatic disease. Therefore, patients with high-risk extremity myxoid liposarcoma should undergo
imaging studies of the chest, abdomen, spine and pelvis as part of their staging and follow-up examinations preferably
with whole body MRI, or CT scans and MRI of the spine and pelvic region for detection of suspected metastatic
disease.
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Background
Sarcomas in adult patients comprise approximately 1% of
all newly diagnosed cancers with an incidence of 3–6 cases
per 100,000 population [1, 2]. Liposarcomas are the second
most common type of soft tissue sarcomas (15–20%), 30–
50% of these are of myxoid or myxoid round cell subtype
[3–5]. Myxoid liposarcoma is a genetically distinct variant
of liposarcoma, characterized by a t(12:16) translocation. A
variable content of round cells is characteristic and known
as a poor prognostic factor (> 5%) [5, 6].
From a clinical point of view an important factor of this
usually slow-growing, deep seated tumour mainly located
in the lower extremities is the propensity to metastasize to
nonpulmonary soft-tissues as the retroperitoneum, the
bone or the contralateral limb [7]. Furthermore, myxoid
liposarcoma is particular radiosensitive thus neoadjuvant
radiation protocols may be very effective [8–10].
The aim of this retrospective study was to analyze the
local control rates, the metastatic pattern and survival of
patients in a consecutive single-institution series.
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Methods
From 1983 to 2015, 43 consecutive patients with myxoid
liposarcoma of the extremities and trunk wall had been
treated in our institution, 37 of them since 2005. All
tumours were located deep to the fascia and had a
diagnosis of myxoid liposarcoma based on histological
features and immunohistochemistry. Thirty-seven pa-
tients had primary, 6 recurrent disease.
Preoperative staging included at least MRI (predomin-
antly) or CT of the primary tumour region and CT
chest. All patients underwent limb-sparing surgical
resection. The margin was defined as R0 if a rim of
sound tissue around the lesion was present (wide resec-
tion) or R1 if the margins were contaminated but the
tumour capsule closed (marginal resection). The French
Federation of Cancer Centers grading system was used
to assign tumour grade [11]. All patients were followed
routinely for evidence of local recurrence or distant
metastasis.
For statistical analysis, overall and recurrence-free
survival were calculated by the Kaplan-Meier method.
Univariate subgroup analysis were done using the log-
rank test (time-to-event data) or the chi-square test. For
multivariate analysis a Cox proportional-hazard regres-
sion model was used. Significance analysis was per-
formed using the log-rank test, the Chi-Square test or
the Cox proportional-hazards regression. The data ana-
lysis software used was MedCalc®.
Results
The mean age of the 21 male and 22 female patients was
48.6 years (range, 18–83). The lower extremity was
involved in 40 cases (25 thigh, 9 lower calf, 5 popliteal
region, 1 ft), the upper arm in 1 and the trunk in 2 pa-
tients. The mean tumour size was 12 cm (range, 1–33).
The mean duration of symptoms was 15 months (range,
0–71), 35 (81%) patients complained of swelling, 5 (12%)
of pain. Neurological impairment (sensory) or restriction
of movement was seen occasionally. Forty patients had a
biopsy or histology from previous surgeries, in 3 cases
surgery was done as excisional biopsy. In 3 patients
metastatic disease was evident at the time of surgery (2
primary, one of them also in local recurrence). The meta-
static lesions were found in the retroperitoneal space, the
lumbar spine and the lymph nodes of the pelvis.
In 31 cases a wide (R0) resection and in 12 a marginal
(R1) resection was achieved. In wide resections the mar-
gins were smaller than 1 mm in 9 patients, between 1
and 5 mm in 11 and larger than 5 mm in 11 patients.
Grading was G1 in 14, G2 in 25 and G3 in 4 cases.
Surgical complications included transient neurapraxia
in 7 patients, prolonged wound healing in 10, hematoma
or seroma in 7, lymphedema in 3, infection in 1 and
fractures in 3 (all after periostal resection and radiother-
apy). In total 14 surgical revisions had to be performed.
Twenty-one patients received postoperative and 11
patients preoperative radiation therapy. Indication for
radiation therapy was seen generally in patients with
G2/G3 lesions or after marginal resection in G1 lesions.
Chemotherapy of variable protocols had been applied in
22 patients.
Nine patient died in follow-up, 4 of them had proven
metastatic disease disease. The median follow-up of the
surviving was 46 months (range, 2–305). Nine patients
had a follow-up of less than 24 months, 4 of them less
than 12 months.
Fig. 1 Effect of radiotherapy on local recurrence free survival
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5-year local recurrence free survival was 82%. In total 4
(9.3%) patients developed local recurrences 21, 34, 42 and
49 months after surgery. All of them had a marginal (R1)
resection (4/12 R1, 0 of 31 R0; p = 0.0034) and suffered
from G2 tumours (n.s.). Two of them had primary tu-
mours, 2 had been treated for locally recurrent disease
(p = 0.034). All 4 received radiation therapy (2 preopera-
tive, 2 postoperative). Only one of those 4 had metastatic
disease (initially) and deceased in follow-up. Local recur-
rence free survival in those patients with risk factors
necessitating radiation therapy was not significantly differ-
ent than the local recurrence free survival in patients
without (Fig. 1). In one patient metastatic disease
developed 2 months after resection of a primary tumour
retro- and intraperitoneal, all 3 patients with preexisting
metastatic disease showed progression. Overall survival
was 81% after 5 years and 72% after 10 years (Fig. 2), pro-
gression free survival was 78% after 5-years (Fig. 3).
Patients with primary tumours had a mean overall survival
of 196 months in recurrent disease 60 months respectively
(n.s.). In multivariate analysis the patient and tumour-
dependent factors as age, Grading and size proved to be
significant on overall survival. Including recurrent disease,
only age and grading remained significant (Table 1).
Fig. 2 Overall survival in 43 patients with myxoid liposarcoma
Fig. 3 Progression free survival in 43 patients with myxoid liposarcoma
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According to univariate analysis, only age over 48 years
and presence or development of distant metastasis had a
significant impact on overall survival (Fig. 4).
Discussion
The crude rate of local recurrences (LR) and distant me-
tastasis (DM) was 9% each. Overall survival (OS) was
81% after 5 years and 72% after 10 years. These results
seem to compare favourably with published series
reporting LR rates of 13–33%, DM rates of 11–38% ad
10-year OS rates of 55–86%, although age distribution
and tumour sizes (our mean 12 cm, published 9–14 cm)
were similar in our compared to the mentioned studies
[12–18]. The in literature described shorter OS in recur-
rent cases failed significance in this series. We identified
tumour size, grading and age with a cut off of 45–
60 years as prognostic factors regarding overall survival
according to multivariate analysis [13, 15, 18, 19]. In
contrast, we could not verify a significant negative im-
pact of recurrent disease with regard to OS as reported
by other investigators, probably due to the small number
of patients. Obviousely these patients are a selected
group as they have already recurred. They are likely to
be more biologically aggressive as evidenced by the fact
Table 1 Cox proportional-hazards regression of grading and
size of the tumor and age of the patient
Factor P HR 95% CI
Age 0,0027 1,16 1,05–1,27
Grading 0,0239 26,30 1,54–448,91
Size 0,1961 1,07 0,97–1,18
Primary/Recurrent 0,9607 0,00 0
HR indicates hazards ratio; CI 95% confidence interval
Fig. 4 Overall survival in dependence to different clinical parameters
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that out of our 6 patients 3 (50%) developed a relapse (2
local and 1 distant).
As shown in Fig. 4 grading has an impact, mainly be-
tween grade 1 and 2, weaker between 2 and 3, as also
described by Fiore et al. [17]. We did not compare the
amount of the round cell component with a cut-off level
of 5% to differentiate pure myxoid liposarcoma (MLPS)
from round cell liposarcoma (RCLPS). MLPS tumours
always were graded 1, there as RCLPS may reflect the
worse survival in in the group of G2 or 3 tumours.
Metastatic disease has a strong impact on survival
with a poor outcome. All our 4 patients who had MD at
diagnosis or developed MD in the course of the disease
died with a median survival of 33 months. This com-
paratively long survival in MD stands in contrast with
other metastasized soft tissue sarcomas but represents
the experience of other authors, too [7, 20]. The
distinctive pattern of MD is well known in myxoid lipo-
sarcoma. Common sites are the retroperitoneum,
abdominal wall and abdominal cavity [7]. Schwab et al.
reported 17% of patients developing skeletal metastases,
more than one-half of metastatic events in their series
[21]. Estourgie et al. described 13 of 14 patients with
MD had extrapulmonary lesions [20]. Because of MD
developing also in soft tissues, multicentric lesions at
diagnosis should be seen critically and may represent in
fact MD [22–24]. This metastasis in fat-bearing areas is
unique and might be contributed by the expression of
high levels of adipophilin and chemokine (C-X-C motif )
receptor 4 (CXCR4), which are both correlated with adi-
pogenesis and metastasis [25].
Conventional methods of imaging as chest x-rays, CT
or even PET-scans well established in other soft tissue
sarcomas may fail in detecting metastastic disease in
myxoid liposarcoma.
In one of our metastatic patients, even FDG-PET-CT
was not able to detect the skeletal lesion as shown in Fig. 5
[26–28]. In a 2010 published survey all 8 patients with
skeletal MD were positive on MRI, 2 out of 4 were nega-
tive in bone scans and 6 out of 8 were negative in CT
scans [29]. Therefore WBMRI seems to be the most
reliable method at present. For example Seo et al. demon-
strated sensitivity and specifity rates of 80%/97% in soft-
tissue lesions and 85%/99% in bony lesions respectively in
a series of 15 patients [30]. Stevenson et al. reported 28
patients who received whole-body MRI and CT. Of 38 le-
sions found on MRI, 29 were located inside a correspond-
ing CT field of view but only 5 of 8 soft-tissue lesions and
none of 21 bony lesions were detected [31].
Patients with positive surgical margins had a 30% risk
of LR compared to 0% in wide resections. But this did
not influence OS neither if we correlated it to margins
nor to LR itself. Only one out of 4 patients with LR
developed DM. In literature this is discussed controversially.
Margins seem to influence disease specific survival but
not metastasis-free survival [32]. This may be caused by
the inclusion of patients with critical locations as retroper-
itoneum or head and neck in this studies, not included in
this series. Further on, we found a clear but insignificant
trend between larger tumour size and the presence of con-
taminated margins.
Interestingly, in this study radiation therapy had a great
influence on therapy by decreasing the size of many tu-
mours in a significant proportion, whereas it did not influ-
ence LR. This is in contrast to Guadagnolo et al. from the
MDACC where in 11 patients with positive surgical
margins and radiotherapy (median dose 50 Gy) no one
showed LR [8]. Chung et al. from Toronto published a
98% LR-free 5-year survival with only 2 recurrences in 88
patients [9]. Using radiotherapy in marginal or even intra-
lesional resections in 10 patients the addition of radiother-
apy resulted in no local relapse at a mean follow-up of
58 months [33]. Even in a hypofractionated protocol (5 ×
5 Gy followed by immediate surgery) in 32 patients a 5-
year LR of 10% was achieved [34]. In many other
Fig. 5 a-c 41-year old patient with solitary metastatic disease in the
sacrum (S3) 6 years after surgery of the primary in the right calf. Lesion
clearly detectable on MRI (a) but not on CT (b) or PET-CT scan (c)
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retrospective studies, as in ours, in which radiation is part
of therapy in selected cases a strong bias with more
relevant risk factors in patients in the radiotherapy
group might influence the result. However, the effect
of neoadjuvant radiotherapy on tumour size could be
seen in many of our cases. This was not part of this
study protocol but as described by Pitson et al. in 16
patients 50 Gy of preoperative radiotherapy induced a
significant reduction of 59% in the mean MRI tumour
volume [10].
Chemotherapy has been applied in many of our cases
due to a general regime in soft tissue sarcomas in our
sarcoma center. Going back in literature doxorubicin-
and dacarbazine-based chemotherapy had been proven
to be effective in myxoid liposarcoma [35]. More
recently trabectedin had shown beneficial effects both
as second-line chemotherapy and in neoadjuvant pro-
tocols [36, 37].
Conclusion
In summary patients with myxoid liposarcomas generally
have a good prognosis. Overall survival was 72% after
10 years, local recurrence was seen only in 9% of the pa-
tients treated with limb-sparing surgery and risk-adapted
radiation therapy. Preoperative radiation therapy further
provides a substantial effect in decreasing tumour size.
This particular subtype of soft tissue sarcomas has specific
characteristics as a distinct pattern of nonpulmonary
metastatic disease. Therefore, patients with high-risk ex-
tremity myxoid liposarcoma should undergo imaging
studies of the chest, abdomen, spine and pelvis as part of
their staging and follow-up examinations preferably with
whole body MRI, or CT scans and MRI of the spine and
pelvic region for detection of suspected metastatic disease.
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